Literature DB >> 30659856

Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients.

Olivier Marion1, Nicolas Capelli2, Sebastien Lhomme3, Martine Dubois2, Mélanie Pucelle4, Florence Abravanel3, Nassim Kamar5, Jacques Izopet6.   

Abstract

OBJECTIVES: Hepatitis E virus genotype 3 (HEV3) is responsible for acute and chronic liver disease in solid organ transplant (SOT) recipients. HEV was recently found in the urine of some acutely and chronically genotype 4-infected patients.
METHODS: We examined the urinary excretion of HEV3 by 24 consecutive SOT recipients at the acute phase of HEV hepatitis and characterized the excreted virus.
RESULTS: Urinary HEV RNA was detected in 12 (50%) of the 24 transplanted patients diagnosed with HEV hepatitis. Urinary HEV antigen (Ag) was detected in all but one of the patients (96%). The density of RNA-containing HEV particles in urine was low (1.11-1.12 g/cm3), corresponding to lipid-associated virions. The urinary HEV RNA/Ag detected was not associated with impaired kidney function or de novo proteinuria. Finally, there was more HEV Ag in the serum at the acute phase of HEV infection in SOT recipients whose infection became chronic.
CONCLUSIONS: HEV3 excreted via the urine of SOT recipients at the acute phase of HEV hepatitis has a lipid envelope. Renal function was not impaired. While urinary HEV Ag was a sensitive indicator of HEV infection, only acute phase serum HEV Ag indicated the development of a chronic infection.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  HEV ORF2 capsid protein; Hepatitis E virus; Transplantation; Urine

Year:  2019        PMID: 30659856     DOI: 10.1016/j.jinf.2019.01.004

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

1.  Evaluation of hepatitis E antigen kinetics and its diagnostic utility for prediction of the outcomes of hepatitis E virus genotype 1 infection.

Authors:  Mohamed A El-Mokhtar; Haidi Karam-Allah Ramadan; Muhamad R Abdel Hameed; Ayat M Kamel; Sahar A Mandour; Maha Ali; Mohamed A Y Abdel-Malek; Doaa M Abd El-Kareem; Sara Adel; Eman H Salama; Khaled Abo Bakr Khalaf; Ibrahim M Sayed
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

2.  Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin.

Authors:  Sebastien Lhomme; Swati DebRoy; Nassim Kamar; Florence Abravanel; David Metsu; Olivier Marion; Chloé Dimeglio; Scott J Cotler; Jacques Izopet; Harel Dahari
Journal:  Viruses       Date:  2019-07-09       Impact factor: 5.048

3.  Optimized Hepatitis E Virus (HEV) Culture and its Application to Measurements of HEV Infectivity.

Authors:  Nicolas Capelli; Martine Dubois; Mélanie Pucelle; Isabelle Da Silva; Sébastien Lhomme; Florence Abravanel; Sabine Chapuy-Regaud; Jacques Izopet
Journal:  Viruses       Date:  2020-01-24       Impact factor: 5.048

Review 4.  Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections.

Authors:  Sébastien Lhomme; Olivier Marion; Florence Abravanel; Jacques Izopet; Nassim Kamar
Journal:  J Clin Med       Date:  2020-01-24       Impact factor: 4.241

Review 5.  Advances in Hepatitis E Virus Biology and Pathogenesis.

Authors:  Shaoli Lin; Yan-Jin Zhang
Journal:  Viruses       Date:  2021-02-09       Impact factor: 5.048

6.  Characterization of Chronic Hepatitis E Virus Infection in Immunocompetent Rabbits.

Authors:  Chunnan Liang; Chenyan Zhao; Tianlong Liu; Bo Liu; Zhiguo Liu; Huili Huang; Wei Liu; Minghai Zhao; Nan Xu; Qiong Lu; Jianhui Nie; Li Zhang; Weijin Huang; Ruiping She; Youchun Wang
Journal:  Viruses       Date:  2022-06-09       Impact factor: 5.818

Review 7.  Hepatitis E Virus Immunopathogenesis.

Authors:  Kush Kumar Yadav; Scott P Kenney
Journal:  Pathogens       Date:  2021-09-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.